Fox Business
29 Jun 2026, 00:06 UTC · 3h ago
The overlooked reason why new drugs take so long—and the $10 trillion fix
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

Fox Business
29 Jun 2026, 00:06 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

What the story claims
4 claims · each scored for market impact
A new report suggests that reducing the FDA drug review process by one year could generate over $10 trillion in economic value. — Such a massive increase in economic value and faster time-to-market would significantly boost the valuation of biotech and pharmaceutical companies.
+0.60Economist Tomas Philipson warns that China's faster and lower-cost clinical trial system could lure drug development investment away from the U.S. — Capital flight from U.S. medical innovation to China represents a structural risk to the domestic healthcare investment landscape.
-0.40The Unleash Prosperity report proposes using artificial intelligence in drug reviews to accelerate the approval of medicines. — AI integration in regulatory workflows would lower operational costs and R&D timelines for drug manufacturers.
+0.30Continue reading
6 related stories
Top 3 movers · tap to explore
Faster FDA approvals are argued to potentially lower prescription drug costs by increasing competition between manufacturers. — Increased competition typically puts downward pressure on drug pricing and profit margins for established pharmaceutical firms.
-0.20Which stocks this story touches
Mentioned only as a social media link (Facebook) without any business context.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.

Newsfile Corp
11h ago